Clinical Trial Update: Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) [Phase 2]

View source ↗

Summary

A completed Phase II extension study evaluating imatinib mesylate in patients with malignant gastrointestinal stromal tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED